

# China Diagnostic Reagent Industry Report, 2013-2016

https://marketpublishers.com/r/C2A95AF875BEN.html Date: July 2014 Pages: 140 Price: US\$ 2,400.00 (Single User License) ID: C2A95AF875BEN

## **Abstracts**

With the accelerated aging of the Chinese population, the increase of personal health expenditure as well as the improved medical care facilities and government health care system, China diagnostic reagent industry has been developing quickly, especially in vitro diagnostic reagents occupy over 90%. In 2013, Chinese in vitro diagnostics market size reached RMB22.98 billion, of which RMB16.61 billion came from in vitro diagnostic reagents.

Chinese in vitro diagnostic reagent market consists of biochemical diagnostic reagents, immunodiagnostic reagents and molecular diagnostic reagents. Among them, the immune reagents and biochemical reagents account for a relatively higher combined proportion, such as around 65% in 2013.

Currently, about 40%-50% share of the Chinese in vitro diagnostics market has been dominated by foreign companies represented by Roche, Siemens, Abbott and Johnson & Johnson. Although there are 300-400 local enterprises in China in vitro diagnostics industry, the top ten Chinese companies which rank by production scale only seize 30% market share, reflecting a low industry concentration degree.

Mindray Medical, KHB, Fosun Pharmaceutical, Maker Biotechnology and Da An Gene act as giants in China in vitro diagnostics industry. Especially, Mindray Medical and KHB achieved the respective in vitro diagnostics revenue of RMB2.0458 billion and RMB1.0572 billion in 2013, accounting for 13.5% of the total jointly.

In 2014, a number of local Chinese diagnostic reagent companies (including BSBE, Maker Biotechnology, Health BioMed, Wondfo, Thalys) intend to step in the capital market through IPO because they are optimistic about the prospects of the diagnostic reagent industry; the raised funds will be used in the expansion of the existing projects or the construction of new projects. SHINVA, Humanwell Healthcare and Zhongyuan



Union Stem Cell Bioengineering have entered the diagnostic reagent industry through acquisitions.

#### The report covers the following:

Status quo of China diagnostic reagent industry, including overview, market structure, import, export, competition pattern and so on;

Development environments and trends of China diagnostic reagent industry, embracing macroeconomy, medical situation, and relevant policies;

Operation and diagnostic reagent business of 17 major companies in China diagnostic reagent industry.



## Contents

#### **1 OVERVIEW OF DIAGNOSTIC REAGENT INDUSTRY**

- 1.1 Definition
- 1.2 Classification
- 1.3 Industry Chain

#### 2 STATUS QUO OF CHINA DIAGNOSTIC REAGENT INDUSTRY

- 2.1 Overview
- 2.2 Market Structure
- 2.3 Import and Export
  - 2.3.1 Import
  - 2.3.2 Export
- 2.4 Competition Pattern
- 2.5 Market Segments
  - 2.5.1 Biochemical Diagnostic Reagents
  - 2.5.2 Immunodiagnostic Reagents
  - 2.5.3 Molecular Diagnostic Reagents
  - 2.5.4 Comprehensive In Vitro Diagnostic Reagents

### 3 DEVELOPMENT ENVIRONMENTS AND TRENDS OF CHINA DIAGNOSTIC REAGENT INDUSTRY

- 3.1 Positive Factors
  - 3.1.1 Macroeconomy
  - 3.1.2 Medical Care
  - 3.1.3 Policies
- 3.2 Trends
  - 3.2.1 Biochemical Immunodiagnostics is still the Mainstream
  - 3.2.2 High Industrial Concentration Degree
  - 3.2.3 Integrated Enterprises will See Better Development

#### 4 MAJOR ENTERPRISES

4.1 Shanghai Kehua Bio-engineering Co., Ltd. (KHB)

- 4.1.1 Profile
- 4.1.2 Operation



- 4.1.3 Revenue Structure
- 4.1.4 Gross Margin
- 4.1.5 R & D and Investment
- 4.1.6 Supply and Marketing
- 4.1.7 In Vitro Diagnostics Business
- 4.1.8 Anticipation and Outlook
- 4.2 Beijing Strong Biotechnologies, Inc (BSBE)
  - 4.2.1 Profile
  - 4.2.2 Operation
  - 4.2.3 Revenue Structure
  - 4.2.4 Gross Margin
  - 4.2.5 R & D and Investment
  - 4.2.6 Production and Marketing
  - 4.2.7 Supply and Marketing
  - 4.2.8 Anticipation and Outlook
- 4.3 Da An Gene
  - 4.3.1 Profile
  - 4.3.2 Operation
  - 4.3.3 Revenue Structure
  - 4.3.4 Gross Margin
  - 4.3.5 R & D and Investment
  - 4.3.6 Diagnostic Reagent Business
  - 4.3.7 Supply and Marketing
  - 4.3.8 Anticipation and Outlook
- 4.4 Fosun Pharmaceutical
  - 4.4.1 Profile
  - 4.4.2 Operation
  - 4.4.3 Revenue Structure
  - 4.4.4 Gross Margin
  - 4.4.5 R & D and Investment
  - 4.4.6 Diagnostic Reagent Business
  - 4.4.7 Anticipation and Outlook
- 4.5 Beijing Leadman Biochemistry Co., Ltd.
  - 4.5.1 Profile
  - 4.5.2 Operation
  - 4.5.3 Revenue Structure
  - 4.5.4 Gross Margin
  - 4.5.5 R & D and Investment
  - 4.5.6 Clients



- 4.5.7 Anticipation and Outlook
- 4.6 Livzon Pharmaceutical Group Inc.
  - 4.6.1 Profile
  - 4.6.2 Operation
  - 4.6.3 Revenue Structure
  - 4.6.4 Gross Margin
  - 4.6.5 R & D
  - 4.6.6 Diagnostic Reagent Business
  - 4.6.7 Anticipation and Outlook
- 4.7 Mindray Medical
  - 4.7.1 Profile
  - 4.7.2 Operation
  - 4.7.3 Revenue Structure
- 4.7.4 Gross Margin
- 4.7.5 R & D and Investment
- 4.7.6 Diagnostic Reagent Business
- 4.7.7 Anticipation and Outlook
- 4.8 Biosino Bio-Technology & Science Inc.
  - 4.8.1 Profile
  - 4.8.2 Operation
  - 4.8.3 Revenue Structure
  - 4.8.4 Gross Margin
  - 4.8.5 Anticipation and Outlook
- 4.9 Maker Biotechnology
  - 4.9.1 Profile
  - 4.9.2 Operation
  - 4.9.3 Revenue Structure
  - 4.9.4 Gross Margin
  - 4.9.5 R & D and Investment
  - 4.9.6 Supply and Marketing
  - 4.9.7 Production and Marketing
- 4.9.8 Anticipation and Outlook
- 4.10 Sinocare
- 4.10.1 Profile
- 4.10.2 Operation
- 4.10.3 Revenue Structure
- 4.10.4 Gross Margin
- 4.10.5 Anticipation and Outlook
- 4.11 Beijing Kinghawk Pharmaceutical Co., Ltd.



- 4.11.1 Profile
- 4.11.2 Operation
- 4.11.3 Revenue Structure
- 4.11.4 Gross Margin
- 4.11.5 Anticipation and Outlook
- 4.12 Bohui Innovation
  - 4.12.1 Profile
  - 4.12.2 Operation
  - 4.12.3 Revenue Structure
  - 4.12.4 Gross Margin
  - 4.12.5 R & D and Investment
  - 4.12.6 Anticipation and Outlook
- 4.13 Health BioMed
  - 4.13.1 Profile
  - 4.13.2 Operation
  - 4.13.3 Revenue Structure
  - 4.13.4 Gross Margin
  - 4.13.5 Supply and Marketing
  - 4.13.6 R & D and Investment
  - 4.13.7 Anticipation and Outlook
- 4.14 Wondfo
  - 4.14.1 Profile
  - 4.14.2 Operation
  - 4.14.3 Revenue Structure
  - 4.14.4 Gross Margin
  - 4.14.5 Supply and Marketing
  - 4.14.6 R & D and Investment
  - 4.14.7 Anticipation and Outlook
- 4.15 Thalys
  - 4.15.1 Profile
  - 4.15.2 Operation
  - 4.15.3 Revenue Structure
  - 4.15.4 Gross Margin
  - 4.15.5 Production and Marketing
  - 4.15.6 Supply and Marketing
  - 4.15.7 R & D and Investment
- 4.15.8 Anticipation and Outlook
- 4.16 SHINVA
  - 4.16.1 Profile



- 4.16.2 Operation
- 4.16.3 Gross Margin
- 4.16.4 Diagnostic Reagent Business
- 4.17 Humanwell Healthcare
- 4.17.1 Profile
- 4.17.2 Operation
- 4.17.3 Diagnostic Reagent Business

### **5 SUMMARY AND FORECAST**

- 5.1 Anticipation and Outlook of China Diagnostic Reagent Industry
- 5.2 Operation Comparison between Major Companies
  - 5.2.1 Revenue
  - 5.2.2 Net Income
  - 5.2.3 Gross Margin
  - 5.2.4 In Vitro Diagnostics Business



## **Selected Charts**

#### SELECTED CHARTS

Classification of In Vitro Diagnostic Reagents (by Detection Principle) In Vitro Diagnostic Reagent Categories and Products (by National Policies) **Diagnostic Reagent Industry Chain** China's In Vitro Diagnostics Market Size, 2009-2013 China's In Vitro Diagnostic Reagent Market Structure, 2013 China's Diagnostic Reagent Import Volume, 2008-2013 China's Diagnostic Reagent Import Value, 2008-2013 China's Diagnostic Reagent Import Sources and Value, 2012-2013 China's Diagnostic Reagent Export Volume, 2008-2013 China's Diagnostic Reagent Export Value, 2008-2013 Top 10 Destinations of Chinese Diagnostic Reagents by Export Volume and Value, 2012-2013 Diagnostic Instrument Comparison between Domestic and Foreign Enterprises Competition Pattern of China Diagnostic Reagent Industry In Vitro Diagnostics Revenue and Market Share of Major Diagnostic Reagent Companies in China, 2013 China's GDP and YoY Growth Rate, 2004-2013 China's Total Population and YoY Growth Rate, 2006-2013 Population of 65-year-old People (or Older) and % of Total Population in China, 2004-2013 China's Health Expenditure and % of GDP, 1980-2013 China's Per Capita Health Expenditure and YoY Growth Rate, 2006-2012 Number of Medical Institutions In China, 2012-2013 Workload of Health Institutions in China, 2012-2013 Main Policies of China Diagnostic Reagent Industry, 2010-2013 **Development Process of Roche Diagnostics** Integrated Development Strategies of Global Leading Diagnostic Reagent Companies KHB's Revenue and Net Income, 2009-2013 KHB's Revenue (by Product), 2009-2013 KHB's Revenue Structure (by Product), 2009-2013 KHB's Revenue (by Region), 2009-2013 KHB's Revenue Structure (by Region), 2009-2013 KHB's Gross Margin, 2009-2013 KHB's Gross Margin (by Product), 2009-2013 KHB's Gross Margin (by Region), 2010-2013



KHB's R & D Costs and % of Total Revenue, 2011-2013 Key National Projects Involved with KHB KHB's Revenue from Top 5 Clients and % of Total Revenue, 2008-2013 Comparison between KHB's Top 5 Clinets, 2012-2013 Comparison between KHB's Top 5 Suppliers, 2012-2013 KHB's Medical Instrument Categories and Products, 2013 KHB's Revenue and Net Income, 2012-2016E BSBE's Revenue and Net Income, 2011-2013 BSBE's Revenue and Structure (by Product), 2011-2013 BSBE's Gross Margin, 2011-2013 Gross Margin of BSBE's Independent Products, 2011-2013 Gross Margin of BSBE's Agent Products, 2011-2013 BSBE's R & D Costs and % of Total Revenue, 2011-2013 **BSBE's Investment Projects and Value** BSBE's Capacity, Output and Sales Volume, 2011-2013 BSBE's Top 10 Products by Sales, 2013 BSBE's Top 5 Raw Material Suppliers, 2011-2013 BSBE's Top 5 Distributors, 2011-2013 BSBE's Revenue and Net Income, 2011-2016E Revenue and Net Income of Da An Gene, 2009-2013 Revenue of Da An Gene (by Product), 2009-2013 Revenue Structure of Da An Gene (by Product), 2009-2013 Revenue of Da An Gene (by Region), 2009-2013 Revenue Structure of Da An Gene (by Product), 2009-2013 Gross Margin of Da An Gene, 2009-2013 Gross Margin of Da An Gene (by Product), 2009-2013 R & D Costs and % of Total Revenue of Da An Gene, 2011-2013 Reagent Revenue and YoY Growth of Da An Gene, 2009-2013 Instrument Revenue and YoY Growth Rate of Da An Gene, 2009-2013 Principal Assets and Business of Da An Gene Medical Resources of Sun Yat-sen University Top 5 Clients of Da An Gene, 2013 Top 5 Clients of Da An Gene, 2012 Top 5 Suppliers of Da An Gene, 2013 Top 5 Suppliers of Da An Gene, 2012 Revenue and Net Income of Da An Gene, 2012-2016E Revenue and Net Income of Fosun Pharmaceutical, 2009-2013 Revenue of Fosun Pharmaceutical (by Business), 2009-2013 Revenue Structure of Fosun Pharmaceutical (by Business), 2009-2013



Revenue of Fosun Pharmaceutical (by Region), 2009-2013 Revenue Structure of Fosun Pharmaceutical (by Region), 2009-2013 Gross Margin of Fosun Pharmaceutical, 2009-2013 Gross Margin of Fosun Pharmaceutical (by Business), 2009-2013 R & D Costs and % of Total Revenue of Fosun Pharmaceutical, 2010-2013 Medical Diagnosis and Medical Equipment Revenue as well as % of Total Revenue of Fosun Pharmaceutical, 2009-2013 Revenue and Net Income of Fosun Pharmaceutical, 2012-2016E Leadman's Revenue and Net Income, 2009-2013 Leadman's Revenue (by Product), 2009-2013 Leadman's Revenue Structure (by Product), 2009-2013 Leadman's Gross Margin, 2009-2013 Leadman's Gross Margin (by Product), 2009-2013 Leadman's R & D Costs and% of Total Revenue, 2011-2013 Leadman's Top 5 Clients, 2013 Leadman's Top 5 Clients, 2012 Leadman's Revenue and Net Income, 2012-2016E Livzon's Revenue and Net Income, 2009-2013 Livzon's Revenue (by Product), 2009-2013 Livzon's Revenue Structure (by Product), 2009-2013 Livzon's Revenue (by Region), 2009-2013 Livzon's Revenue Structure (by Region), 2009-2013 Livzon's Gross Margin, 2009-2013 Livzon's Gross Margin (by Product), 2009-2013 Livzon's Main Diagnostic Reagent Products Revenue and YoY Growth Rate of Livzon's Diagnostic Reagents and Equipment, 2009-2013 Livzon's Revenue and Net Income, 2012-2016E Revenue and Net Income of Mindray Medical, 2009-2013 Revenue of Mindray Medical (by Product), 2009-2013 Revenue Structure of Mindray Medical (by Product), 2009-2013 Gross Margin of Mindray Medical, 2009-2013 R & D Costs and % of Total Revenue of Mindray Medical, 2009-2013 In Vitro Diagnostic Product Revenue and YoY Growth Rate of Mindray Medical, 2009-2013 Revenue and Net Income of Mindray Medical, 2012-2016E Biosino's Revenue and Net Income, 2009-2013 Biosino's Revenue (by Product), 2009-2013



Biosino's Gross Margin, 2009-2013 Biosino's Revenue and Net Income, 2012-2016E Product Structure of Maker Biotechnology Revenue and Net Income of Maker Biotechnology, 2011-2013 Sales and Structure of Independent Products of Maker Biotechnology, 2011-2013 Agent Brand Sales and Structure of Maker Biotechnology, 2011-2013 Sales and Structure of Maker Biotechnology (by Client), 2011-2013 Comparison between Direct sales and Distribution Revenue of Maker Biotechnology (by Region), 2011-2013 Gross Margin of Maker Biotechnology, 2011-2013 R & D Costs and % of Total Revenue of Maker Biotechnology, 2011-2013 Investment Projects and Value of Maker Biotechnology Top 10 Suppliers of Maker Biotechnology, 2012-2013 Dealer Distribution of Maker Biotechnology, 2011-2013 Top 5 Clients of Maker Biotechnology, 2011-2013 Capacity, Output and Sales Volume of Maker Biotechnology, 2011-2013 Comparison between Independent Diagnostic Products and Agent Diagnostic Products of Maker Biotechnology Revenue and Net Income of Maker Biotechnology, 2012-2016E Sinocare's Revenue and Net Income, 2009-2013 Sinocare's Revenue Structure (by Product), 2009-2013 Sinocare's Gross Margin, 2009-2013 Sinocare's Gross Margin (by Product), 2009-2013 Sinocare's Revenue and Net Income, 2012-2016E Revenue and Net Income of Kinghawk Pharmaceutical, 2009-2013 Revenue of Kinghawk Pharmaceutical (by Product), 2010-2012 Revenue Structure of Kinghawk Pharmaceutical (by Product), 2010-2012 Gross Margin of Kinghawk Pharmaceutical, 2009-2013 Gross Margin of Kinghawk Pharmaceutical (by Product), 2010-2012 Revenue and Net Income of Kinghawk Pharmaceutical, 2012-2016E Revenue and Net Income of Bohui Innovation, 2009-2013 Revenue of Bohui Innovation (by Product), 2009-2013 Revenue Structure of Bohui Innovation (by Product), 2009-2013 Gross Margin of Bohui Innovation, 2009-2013 Gross Margin of Bohui Innovation (by Product), 2009-2013 R & D Costs and % of Total Revenue of Bohui Innovation, 2010-2013 Revenue and Net Income of Bohui Innovation, 2012-2016E Revenue and Net Income of Health BioMed, 2011-2013 Revenue and Structure of Health BioMed (by Product), 2011-2013



Revenue and Structure of Health BioMed (by Region), 2011-2013 Revenue and Structure of Health BioMed (by Client), 2011-2013 Gross Margin of Health BioMed, 2011-2013 Gross Margin of Health BioMed (by Product), 2011-2013 Top 5 Suppliers of Health BioMed, 2011-2013 Top 5 Clients of Health BioMed, 2011-2013 R & D Costs and % of Total Revenue of Health BioMed, 2011-2013 In Vitro Diagnostic Items, Product Categories and Operation Modes of Health BioMed Investment Projects and Value of Health BioMed Revenue and Net Income of Health BioMed, 2011-2016E Application and Detection Methods of Wondfo's Products Wondfo's Revenue and Net Income, 2011-2013 Wondfo's Revenue (by Product), 2011-2013 Wondfo's Revenue Structure (by Product), 2011-2013 Wondfo's Revenue (by Region), 2011-2013 Wondfo's Gross Margin, 2011-2013 Wondfo's Gross Margin (by Product), 2011-2013 Wondfo's Top 5 Suppliers, 2011-2013 Wondfo's Top 5 Clients, 2011-2013 Wondfo's R & D Costs and % of Total Revenue, 2011-2013 Wondfo's Investment Projects and Purposes of Raised Funds Wondfo's Revenue and Net Income, 2011-2016E Revenue and Net Income of Thalys, 2011-2013 Revenue and Structure of Thalys (by Business), 2011-2013 Revenue and Structure of Thalys (by Region), 2011-2013 Gross Margin of Thalys, 2011-2013 Gross Margin of Thalys (by Business), 2011-2013 Capacity, Output, Sales Volume, Capacity Utilization and Sales/Output Ratio of Thalys' Independent Products, 2011-2013 Top 5 Clients of Thalys, 2011-2013 Top 5 Suppliers of Thalys, 2011-2013 Sales and R & D COSTS of Thalys' Independent Products, 2011-2013 Investment Projects and Raised Funds of Thalys Revenue and Net Income of Thalys, 2011-2016E SHINVA's Revenue and Net Income, 2009-2013 SHINVA's Gross Margin, 2009-2013 Revenue and Net Income of Humanwell Healthcare, 2009-2013 Chinese In Vitro Diagnostics Market Size, 2012-2016E Revenue Comparison between Major Companies in China Diagnostic Reagent Industry,



#### 2009-2013

Net Income Comparison between Major Companies in China Diagnostic Reagent Industry, 2009-2013

Net Profit Margin Comparison between Major Companies in China Diagnostic Reagent Industry, 2009-2013

Gross Margin Comparison between Major Companies in China Diagnostic Reagent Industry, 2009-2013

In Vitro Diagnostics Revenue Comparison between Major Companies in China Diagnostic Reagent Industry, 2009-2013



### I would like to order

Product name: China Diagnostic Reagent Industry Report, 2013-2016

Product link: https://marketpublishers.com/r/C2A95AF875BEN.html

Price: US\$ 2,400.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/C2A95AF875BEN.html</u>